solanezumab

The search continues.

Eli Lilly and Company has spent three decades and $3 billion in an Ahab-like quest to develop the world’s first effective drug to treat Alzheimer’s disease.

“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”